

Nusinersen

Goal(s):

- Approve nusinersen for funded OHP conditions supported by evidence of benefit (e.g. Spinal Muscular Atrophy)

Length of Authorization:

- Up to 8 months for initial approval and up to 12 months for renewal.

Requires PA:

- Nusinersen

Covered Alternatives:

- Current PMPDP preferred drug list per OAR 410-121-0030 at www.orpdl.org
- Searchable site for Oregon FFS Drug Class listed at www.orpdl.org/drugs/

Approval Criteria		
1. What diagnosis is being treated?	Record ICD-10 code. Go to #2	
2. Is this a request for continuation of therapy?	Yes: Go to Renewal Criteria	No: Go to #3
3. Does the patient have type 1, 2 or 3 Spinal Muscular Atrophy documented by genetic testing and at least 2 copies of the SMN2 gene?	Yes: Go to #4	No: Pass to RPh. Deny; medical appropriateness.
4. Is a baseline motor assessment available such as one of the following functional assessment tools: <ul style="list-style-type: none"> • Hammersmith Infant Neurological Examination (HINE-2) • Hammersmith Functional Motor Scale (HFSME) • Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) • Upper Limb Module (ULM) • 6-Minute Walk Test 	Yes: Go to #5	No: Pass to RPh. Deny; medical appropriateness.

Approval Criteria

<p>5. Is the patient ventilator dependent (using at least 16 hours per day on at least 21 of the last 30 days)?</p> <p>Note: This assessment does not apply to patients who require ventilator assistance</p>	<p>Yes: Pass to RPh. Deny; medical appropriateness.</p>	<p>No: Go to #6.</p>
<p>6. Is the drug being prescribed by a pediatric neurologist or a provider with experience treating spinal muscular atrophy?</p>	<p>Yes: For initial approval, approve 5 doses over 8 months.</p>	<p>No: Pass to RPh. Deny; medical appropriateness.</p>

Renewal Criteria

<p>1. Has the patient's motor function improved as demonstrated by:</p> <ul style="list-style-type: none">• Improvement from baseline motor function score documented within one month of renewal request AND• More areas of motor function improved than worsened	<p>Yes: Approve for 12 months</p>	<p>No: Pass to RPh; Deny; medical appropriateness.</p>
---	--	---

P&T Review: 7/17 (DM); 3/17
Implementation: 9/1/17; 5/17